UK small-cap RNS · 1 Sep 2026
Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.
Sort: Newest · Largest companies
-
14:48
Ramsdens Holdings RFX £206mUpdate On Financing Arrangements(an indirect wholly-owned subsidiary of FirstCash Holdings, Inc.)Takeover target +0.5% on the day
-
13:59
Fundraising, Allotment, TVR & Board Changes FundraiseFurther to its announcement of 21 August 2026, R8 Capital Investments PLC is pleased to announce that the Fundraising has now completed and the Company has allotted and issued 302,393,162 new ordinary shares of £0.0001 each (the "New Ordinary Shares") to the …Dilutive fundraise +0.0% on the day
-
09:31
-
07:28
-
07:01
Renalytix RENX £40mProposed Fundraise FundraiseRaises about £9.5m at a 44.6% premium, funding the Quest rollout, and converts the Heights Capital bonds to equity so no HCM debt remains. Dilution is large, but the pricing is above market.Dilutive fundraise £9.5m · 24% of mcapahead of expectationsoutlook mixedfirst in 11 months +0.0% on the dayMoved: Quest national rollout: Agreement signed; integration pending → Funding raised; integration pending · new: Fundraise and debt conversion – Bookbuild open; first tranche admission expected 7 September
-
07:00
Covenant Waiver ExtensionNorthleaf extends the covenant waiver by only one month to 30 September, the eighth short extension since December. The 2.00% interest uplift continues and refinancing remains unresolved, so LCM stays dependent on lender forbearance.Sale process / strategic review +8.2% on the dayMoved: Strategic review: Review ongoing; waiver extended to 31 August → Review ongoing; waiver extended to 30 September
-
07:00
Bodycote BOY £1,541mRecommended Cash Acquisition of Bodycote plc OfferVeritas firm recommended cash offer of 940p (932.8p cash plus 7.2p interim dividend) converts the board-minded-to-recommend proposal into a firm Rule 2.7 offer, at a stated 36.5% premium to the 3-month undisturbed VWAP.Moved: Possible offers for the company: Two proposals; board minded to recommend both → Firm recommended offer announced by Veritas
-
07:00
Capricorn Energy CNE £291mRecommended Cash Acquisition of Capricorn by DNO OfferDNO's recommended cash offer of US$5.214 (384p) per share tops Genel's 357p offer by about 10%, so shareholders get a better price and the unanimously recommended Genel bid is displaced.Moved: new: DNO offer for the company – Recommended cash offer announced 1 Sep 2026 · Modernised concession agreement ratification: Ratified; ministerial signature still pending → Ratified; ministerial signature still pending
-
07:00
Renalytix RENX £40mCollaboration with Quest DiagnosticsSigns the multi-year national distribution deal with Quest the company was seeking, giving access to ordering via about half of US physicians and hospitals; availability only from Q1 2027, so revenue lags.Moved: National distribution agreement: Contract discussions advancing → Agreement signed with Quest Diagnostics (closed) · new: Quest national rollout – Agreement signed; integration pending
-
07:00
Chariot Limited CHAR £87mIncreasing Exposure to Assets Offshore AngolaIncreasing Economic Exposure to Oil-Producing Assets Offshore AngolaLarge acquisition / reverse takeover +35.3% on the dayMoved: 'Second Angola Block 14 exposure' is the open 'Angola Block 14 funding deal' - continued · Angola Block 14 funding deal: SPA signed; closing expected H2 2026 → SPA and Framework Agreement signed
-
07:00
Futura Medical FUM £2.4mUnaudited Interim Results 2026 ResultsOperating loss narrows to £1.2m from £6.7m, but only because £1.4m of the £1.6m revenue is the one-off Haleon settlement; underlying revenue is £0.2m and cash has fallen to £1.24m.Moved: Going concern and funding: Milestone waived for fee; runway into October 2026 → Material uncertainty; cash £1.06m, runway to October · Strategic review and turnaround: Hybrid model being implemented in the US → Hybrid model executing; MPG US start · Eroxon Intense and WSD4000 development: Eroxon Intense cleared for EEA and UK launch → EU cleared; FDA expected Q4 2026
-
07:00
Finseta PLC FIN £4.0mH1 2026 Trading Update Trading updateFY26 now expected below prior Board expectations, with revenue of about £11m. H1 revenue fell and the adjusted EBITDA loss was c. £1.0m, hit by weak demand, Dubai curtailed by conflict, and a lost currency corridor.Upgrade / downgrade cycle £11.0m · 275% of mcapbelow expectationsoutlook negative, loweredfirst since Oct 2023 −40.5% on the dayMoved: Growth investment and return to cash generation: Fundraise completed; investing, FY25 EBITDA near break-even → Investing; FY26 guidance cut, EBITDA loss in H1 · Dubai and corporate client expansion: Dubai growing ahead of plan; retail endorsement granted → Dubai growing but below expectations
-
07:00
Ampeak Energy secures investment in AW1 projectAmpeak Energy is pleased to announce that JBR Energy Holdings Ltd ("JB Energy"), a special purpose vehicle owned by various Directors of Jones Bros.Moved: new: AW1 battery expansion – Nearing financial close; half of sale funds ringfenced · new: AW1 battery construction – Balance of plant and electrical works on schedule
-
07:00
Wellnex Life Limited WNX £3.7mAnnual Report for Year Ended 30 June 2026 ResultsAudited FY26 shows the October 2025 reset working: revenue up 5.1% and the net loss cut by 70.8%. The EBITDA loss fell from about A$12.1m to A$1.7m, although the company is still loss-making.Moved: Increase revenue strongly and gross margin in FY26 through a more disciplined tr: on_track → missed – Full-year revenue grew only 5.1% and gross margin rose to 30.2% from 29%, which is not the strong increase promised. · Funding and liquidity position: Binding sale agreed; funding to be resolved at completion → Going-concern uncertainty; relies on Pain Away completion · Sale of Pain Away: Binding agreement signed; awaiting shareholder approval → Binding agreement; awaiting shareholder approval
-
07:00
Unaudited Interim Results Update ResultsH1 operating loss of c. £3.4m is far worse than the £0.9m underlying loss a year earlier, and a c. £14.0m Hawk JV write-down follows. This deepens July's profit shortfall.Moved: Funding facility capacity and maturity: Further £0.5m related-party bond; trading weak through June → £4m related-party liquidity facility signed 28 August · New CEO and profit recovery: Charnley CEO from 10 July; efficiency measures → Strategic plan and Channel Islands review launched
-
07:00
Sale of three handysize vesselsAgrees sale of three handysize vessels for about $48.6m, above March book values, leaving two vessels and funding another redemption. Two related-party deals with the CEO's T3 add a governance point, but the Board and sponsor call them fair.Moved: Managed realisation vessel sales: Five vessels left, all on time charter → Three-vessel sale agreed; two vessels left · Third return of capital: $45.0m paid around 24 July 2026 → Third return paid; fourth planned after sales